Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
NCT02419560
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, Mantle-Cell
Recurrent Lymphoma, Mantle-Cell
Interventions
DRUG:
ABT-199 and Ibrutinib Combination
Sponsor
Craig Portell, MD
Collaborators
[object Object]